Tempered signal strength via low-dose MEK inhibition optimizes therapeutic performance of engineered T cells.

Saved in:
Bibliographic Details
Title: Tempered signal strength via low-dose MEK inhibition optimizes therapeutic performance of engineered T cells.
Authors: Füchsl F; School of Medicine and Health, III Medical Department, TUM University Hospital, Technical University of Munich, Munich, Germany franziska.fuechsl@tum.de.; Center for Translational Cancer Research (TranslaTUM), Technical University of Munich, Munich, Germany., Schwanzer A; School of Medicine and Health, III Medical Department, TUM University Hospital, Technical University of Munich, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), Technical University of Munich, Munich, Germany., Faber M; School of Medicine and Health, III Medical Department, TUM University Hospital, Technical University of Munich, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), Technical University of Munich, Munich, Germany., Rieger L; School of Medicine and Health, III Medical Department, TUM University Hospital, Technical University of Munich, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), Technical University of Munich, Munich, Germany., Zuleger G; School of Medicine and Health, III Medical Department, TUM University Hospital, Technical University of Munich, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), Technical University of Munich, Munich, Germany., Auf der Maur P; School of Medicine and Health, III Medical Department, TUM University Hospital, Technical University of Munich, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), Technical University of Munich, Munich, Germany., Cruz E; School of Medicine and Health, III Medical Department, TUM University Hospital, Technical University of Munich, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), Technical University of Munich, Munich, Germany., Braun S; Institute of Medical Microbiology Immunology and Hygiene, Technical University of Munich, Munich, Germany., Öllinger R; Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany., Busch DH; Institute of Medical Microbiology Immunology and Hygiene, Technical University of Munich, Munich, Germany.; German Center for Infection Research, Munich Site, Munich, Germany., Bassermann F; School of Medicine and Health, III Medical Department, TUM University Hospital, Technical University of Munich, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), Technical University of Munich, Munich, Germany.; Bavarian Cancer Research Center, Erlangen, Germany.; German Cancer Consortium (DKTK), partner-site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany., Krackhardt AM; School of Medicine and Health, III Medical Department, TUM University Hospital, Technical University of Munich, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), Technical University of Munich, Munich, Germany.; German Cancer Consortium (DKTK), partner-site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Dec 01; Vol. 13 (12). Date of Electronic Publication: 2025 Dec 01.
Publication Type: Journal Article
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2051-1426
DOI:10.1136/jitc-2025-012800